Although scientists have had access to human embryonic stem cells for a decade, precisely how the all-purpose cell gives rise to all other cells in the body and why others do not remains a fundamental mystery of biology.
Jose Zepeda, of Ellsworth, Wis., peers into a microscope while participating in a summer science camp hosted at the WiCell Research Institute at University Research Park the week of July 14. Designed for rural Wisconsin high school students such as Zepeda, the four-day outreach program provides hands-on learning experiences with human embryonic stem cells, working …
When forming attitudes about embryonic stem cell research, people are influenced by a number of things. But understanding science plays a negligible role for many people, according to a recent UW-Madison study.
Invitrogen Corp. and the Wisconsin Alumni Research Foundation announced today (May 8) that they have signed a license for human embryonic stem cell (hESC) patents for the development of research tools.
Timothy Kamp, a professor of medicine and physiology at the University of Wisconsin School of Medicine and Public Health, has been awarded the inaugural Schuster Prize for excellence in advancing cardiovascular medicine at the school.
Stem cell scientist James Thomson has been named one of Time magazine’s “World’s Most Influential People,” with Shinya Yamanaka of Kyoto University. Last year, they each discovered a way to give human skin cells many of the characteristics of embryonic stem cells, an advance that avoids the destruction of embryos.
Pioneering University of Wisconsin-Madison stem cell scientist James Thomson was elected today (April 29) to the National Academy of Sciences.
A cadre of North America’s leading stem cell scientists will land in Madison April 16 for the third annual Wisconsin Stem Cell Symposium.
Erik Forsberg has been named to the newly created position of executive director of the WiCell Research Institute. In this position, Forsberg will direct all operations of the private, non-profit institute, a supporting organization of the University of Wisconsin-Madison that provides core services to UW-Madison stem cell researchers and operates the National Stem Cell Bank.
Peter D. Kiernan, III, chair of the Christopher and Dana Reeve Foundation, will provide the keynote address at the World Stem Cell Summit Sept. 22-23, 2008, at the Alliant Energy Center in Madison.
The UW scientist who first brought stem cells into the scientific spotlight — a discovery that sparked a volatile debate of political and medical ethics — doesn’t seek fame for himself. So when you are the go-to guy for everybody who wants access to James Thomson, a man who’d much rather be in the lab than in the media’s glare, you learn to say no more often than you’d like.
Researchers, business representatives, philanthropists, bioethicists and educators from around the world will be invited to Madison for the World Stem Cell Summit at the Alliant Energy Center on Sept. 22-23, 2008.
BioTime, Inc. (OTCBB: BTIM) has signed a licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for 173 patents and patent applications relating to human embryonic stem cell technology created by James Thomson at the University of Wisconsin-Madison.
For the first time, scientists have used human embryonic stem cells to predict the toxic effects of drugs and provide chemical clues to diagnosing disease.
In a paper to be published Nov. 22 in the online edition of the journal Science, a team of University of Wisconsin-Madison researchers reports the genetic reprogramming of human skin cells to create cells indistinguishable from embryonic stem cells.
When University of Wisconsin-Madison researchers succeeded in reprogramming skin cells to behave like embryonic stem cells, they also began to redefine the political and ethical dynamics of the stem-cell debate, a leading bioethicist says.
With the help of a $7.2 million grant from the National Institutes of Health (NIH), a team of University of Wisconsin-Madison researchers will explore the potential of stem cells and natural growth factors to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.
The National Stem Cell Bank has announced that it has received select human embryonic stem cell lines from Novocell, a leading stem cell engineering company based in San Diego. With the addition of the new lines, the National Stem Cell Bank will have on deposit 14 of the 21 cell lines listed on the National Institutes of Health (NIH) federal registry.
In a study that demonstrates the promise of cell-based therapies for diseases that have proved intractable to modern medicine, a team of scientists from the University of Wisconsin-Madison has shown it is possible to rescue the dying neurons characteristic of amyotrophic lateral sclerosis (ALS), a fatal neuromuscular disorder also known as Lou Gehrig’s disease.
In an effort to strengthen and sustain its leadership in the companion fields of stem cell research and regenerative medicine, the University of Wisconsin-Madison will establish a new Stem Cell and Regenerative Medicine Center.